Comparing adjuvanted H28 and modified vaccinia virus ankara expressingH28 in a mouse and a non-human primate tuberculosis model.
Here we report for the first time on the immunogenicity and protective efficacy of a vaccine strategy involving the adjuvanted fusion protein "H28" (consisting of Ag85B-TB10.4-Rv2660c) and Modified Vaccinia Virus Ankara expressing H28. We show that a heterologous prime-boost regimen involv...
Main Authors: | Rolf Billeskov, Jan P Christensen, Claus Aagaard, Peter Andersen, Jes Dietrich |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23977248/?tool=EBI |
Similar Items
-
Testing the H56 Vaccine Delivered in 4 Different Adjuvants as a BCG-Booster in a Non-Human Primate Model of Tuberculosis.
by: Rolf Billeskov, et al.
Published: (2016-01-01) -
Distinct differences in the expansion and phenotype of TB10.4 specific CD8 and CD4 T cells after infection with Mycobacterium tuberculosis.
by: Truc Thi Kim Thanh Hoang, et al.
Published: (2009-01-01) -
CD4 and CD8 T cell responses to the M. tuberculosis Ag85B-TB10.4 promoted by adjuvanted subunit, adenovector or heterologous prime boost vaccination.
by: Tara Elvang, et al.
Published: (2009-01-01) -
Induction of Influenza (H5N8) Antibodies by Modified Vaccinia Virus Ankara H5N1 Vaccine
by: Rory D. de Vries, et al.
Published: (2015-06-01) -
Clinical development of Modified Vaccinia virus Ankara vaccines
by: Gilbert, S
Published: (2013)